Experienced in Acute Lymphoblastic Leukemia (ALL)

Dr. Mark Fluchel

Pediatric Hematology Oncology
100 Mario Capecchi Dr, 
Salt Lake City, UT 
Clinical Trials:Currently Recruiting for 2 Trials
Offers Telehealth
Experienced in Acute Lymphoblastic Leukemia (ALL)
100 Mario Capecchi Dr, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Fluchel is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Fluchel is rated as an Experienced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Non-Langerhans-Cell Histiocytosis, Hemophagocytic Lymphohistiocytosis, Histiocytosis, and Reticulohistiocytoma.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Acute Lymphoblastic Leukemia (ALL).

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in UT
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 5 Less Insurance Carriers -

Locations

100 Mario Capecchi Dr, Salt Lake City, UT 84113

Additional Areas of Focus

Dr. Fluchel has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
Enrollment Status: Recruiting
Publish Date: September 22, 2025
Intervention Type: Drug
Study Drug: Difluoromethylornithine (DFMO)
Study Phase: Phase 2
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Prednisone, Vinblastine, Mercaptopurine, Indomethacin, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, Intravenous immunoglobulin
Study Phase: Phase 2/Phase 3
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.
Enrollment Status: Completed
Publish Date: August 06, 2024
Intervention Type: Drug
Study Drugs: Nifurtimox, Cyclophosphamide, Topotecan
Study Phase: Phase 2
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Emapalumab
Study Phase: Phase 3
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
A Phase 2/3 Open-label Single Arm Multicentre Study to Assess Safety Tolerability Pharmacokinetics and Efficacy of i.v. Administrations of NI-0501 an Anti-IFNγ mAb in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Biological
Study Phase: Phase 2/Phase 3
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: May 20, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

43 Total Publications

Palliative and End-of-Life Disparities for Pediatric Hispanic, Spanish-preferring Patients With Cancer.
Palliative and End-of-Life Disparities for Pediatric Hispanic, Spanish-preferring Patients With Cancer.
Journal: Journal of pediatric hematology/oncology
Published: December 15, 2024
Similar Doctors
Elite in Acute Lymphoblastic Leukemia (ALL)
Dr. Michael A. Pulsipher
Pediatric Hematology Oncology
Elite in Acute Lymphoblastic Leukemia (ALL)
Dr. Michael A. Pulsipher
Pediatric Hematology Oncology

Primary Children's Hospital - Hematology Oncology

100 North Mario Capecchi Drive, Suite 1400, 
Salt Lake City, UT 
 (0.1 miles away)
801-662-4700
Experience:
35+ years
Languages Spoken:
English, Japanese
See accepted insurances
Accepting New Patients

Michael Pulsipher is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Pulsipher has been practicing medicine for over 35 years and is rated as a Distinguished provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Graft Versus Host Disease (GvHD), Leukemia, Severe Combined Immunodeficiency (SCID), and Bone Marrow Transplant. Dr. Pulsipher is currently accepting new patients.

Distinguished in Acute Lymphoblastic Leukemia (ALL)
Dr. Michael W. Boyer
Pediatric Hematology Oncology
Distinguished in Acute Lymphoblastic Leukemia (ALL)
Dr. Michael W. Boyer
Pediatric Hematology Oncology
100 N Medical Dr, Bmt, 
Salt Lake City, UT 
 (0.2 miles away)
801-585-3229
Languages Spoken:
English
See accepted insurances

Michael Boyer is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Boyer is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Hepatic Venoocclusive Disease with Immunodeficiency, Childhood Acute Myeloid Leukemia, and Bone Marrow Transplant.

Distinguished in Acute Lymphoblastic Leukemia (ALL)
Dr. Jennifer L. Mcneer
Pediatric Hematology Oncology
Distinguished in Acute Lymphoblastic Leukemia (ALL)
Dr. Jennifer L. Mcneer
Pediatric Hematology Oncology

Primary Children's Hospital - Hematology Oncology

100 North Mario Capecchi Drive, Suite 1400, 
Salt Lake City, UT 
 (0.1 miles away)
801-662-4700
Experience:
16+ years
Languages Spoken:
English
See accepted insurances

Jennifer Mcneer is a Pediatric Hematologist Oncology provider in Salt Lake City, Utah. Dr. Mcneer has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of Acute Lymphoblastic Leukemia (ALL). Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Febrile Neutropenia, Infantile Neutropenia, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fluchel's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile